Reynolds CardioCollect

Page A2

Reynolds Medical Ltd. 510(k) Submission CardioCollect 510(k) Summary

DEC 1 3 2001

(1) Submitter Information

Name: Reynolds Medical Ltd.

Address:

1 Harforde Court John Tate Road Hertford, Herts. SG13 7NW ENGLAND

Telephone Number: 44-1992-507700

Contact Person:

Dr. George Myers (Official Correspondent) Medsys Inc. 377 Route 17 S Hasbrouck Heights, NJ 07604 Telephone 201-727-1703 Fax 201-727-1708

Date Prepared: October 3, 2001

(2) Name of Device

Trade Name: CardioCollect

Common Name: Ambulatory electrocardiograph without analysis Classification name: Electrocardiograph (74DPS, 870.2340)

(3) Equivalent legally-marketed devices.

Agilent M2662A, K002459

(4) Description

CardioCollect is a small, portable rechargeable-battery-powered digital electrocardiograph that is intended to be used by technicians to acquire 12-lead ECG's from up to 40 patients, and then print them or store them digitally in the patient's record in a computer (or both). The unit prints by direct connection to a

printer. Typical recording time is ten seconds; all leads are recorded simultaneously. The unit meets all specifications for 12-lead electrocardiographs. It has a provision for entry of patient data using its keypad.

Records include basic data on patients (name, number, and date of birth) as well as the electrocardiogram, and these can be printed with the tracing.

(5) Intended Use

The Reynolds CardioCollect is a small, portable rechargeable-battery-powered digital electrocardiograph that is intended to be used by technicians to acquire 12-lead ECG's from up to 40 patients, and then print them or store them digitally in the patient's record in a computer (or both).

(6) Performance Data

(a) Non-clinical tests

CardioCollect has passed the tests for ANSI/AAMI EC11, electrocardiographs, and EN 60601-1 (electrical safety) and EN 60601-1-2 (electromagnetic compatibility).

(b) Clinical tests

A series of electrocardiograms has been taken with CardioCollect to show the quality of the tracings made.

(c) Conclusions

CardioCollect is equivalent in safety and efficacy to the legally-marketed predicate devices.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC 1 3 2001

Reynolds Medical Ltd. c/o George H. Myers, Sc.D. Medsys Inc. 377 Route 17 S Hasbrouck Heights, NJ 07604

Re: K013367

Trade Name: CardioCollect Portable Electrocardiograph

Regulation Number: 21 CFR 870.2340 Regulation Name: Electrocardiograph

Regulatory Class: Class II (two)

Product Code: DPS Dated: October 8, 2001 Received: October 10, 2001

Dear Mr. Myers:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Page 2 - George H. Myers, Sc.D.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Bram D. Zuckerman, M.D.

Acting Director

Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Page 1 of 1		
510(k) Number (if known): K	013367	
Indications for Use Form		
Device Name: CardioCollect		
Indications for Use:		
electrocardiograph intended to be to 40 patients, and then print the computer (or both). The unit print	used by technician em or store them ts by direct conne	chargeable-battery-powered digital instead to acquire 12-lead ECG's from up digitally in the patient's record in a ction to a printer. The unit meets also a provision for entry of patient data
(PLEASE DO NOT WRITE BE	ELOW THIS LIN PAGE IF NEEDE	IE – CONTINUE ON ANOTHER (D)
Concurrence of CDF	RH, Office of Dev	rice Evaluation (ODE)
Prescription Use	OR	Over-the-Counter
Per 21 CFR 810.109)		(Optional Format 1-2-96)
Division of Cardiovascular & Res	spiratory Devices	